Understanding the clinical biochemistry of N-terminal pro-B-type natriuretic peptide: The prerequisite for its optimal clinical use

Clinical Laboratory

Volumn 50, Issue 5-6, 2004, Pages 325-331

  Panteghini, Mauro ^a   Clerico, Aldo ^b  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

AN; BNP; Immunoassay; Natriuretic peptide; Nt proBNP; ProBNP; Ventricular function

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; PROTEIN PRECURSOR;

AMINO TERMINAL SEQUENCE; AUTOMATION; CARDIOLOGY; CHEMOLUMINESCENCE; CLINICAL CHEMISTRY; CLINICAL LABORATORY; DATA ANALYSIS; DIAGNOSTIC VALUE; ELECTROIMMUNOASSAY; HEART DISEASE; HUMAN; LABORATORY AUTOMATION; PILOT STUDY; PROTEIN ANALYSIS; RADIOIMMUNOASSAY; REVIEW;

AGE FACTORS; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; EPITOPES; HEART DISEASES; HUMANS; IMMUNOASSAY; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 3042774156     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Wilkins MR, Redondo J, Brown LA. The natriuretic-peptide family. The Lancet 1997;349:1307-10.
2. Stein BC, Levin RI. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998;135:914-23.
3. Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci 1998;95:519-29.
4. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
5. Clerico A, Iervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999;31:487-98.
6. Kay JD, Trichon BH, Kisslo K, et al. Serum brain natriuretic peptide levels cannot differentiate pulmonary disease from left-heart failure if the right ventricle is dilated. Circulation 2003;108:IV-397.
7. Clerico A. Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: are they merely markers of cardiac disease? Clin Chem Lab Med 2002;40:752-60.
8. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003;334:233-9.
9. Sawada Y, Suda M, Yokoyama H, et al. Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin. J Biol Chem 1997;272:20545-54.
10. Pemberton CJ, Johnson ML, Yandle TG, Espiner EA. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 2000;36:355-9.
11. Noe DA. Tissue injury. In: Noe DA (ed) The logic of laboratory medicine, 2nd ed. Baltimore, MD: Urban & Schwarzemberg, 2001:9/1-20.
12. Omland T, Hall C. N-terminal pro-B-type natriuretic peptide. In: Wu AHB (ed) Cardiac markers, 2nd ed. Totowa, NJ: Humana Press, 2003:411-24.
13. Cowie MR, Mendez GF. BNP and congestive heart failure. Progr Cardiovasc Dis 2002;44:293-321.
14. Struthers AD. Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. Heart 2002;87:97-8.
15. Brunner-La Rocca HP, Kiowski W, Ramsay D, Sütsch G. Therapeutic benefits of increasing natriuretic peptide levels. Cardiovasc Res 2001;51:510-20.
16. Luchner A, Hengstenberg C, Löwel H, et al. N-terminal probrain natriuretic peptide after myocardial infarction. A marker of cardio-renal function. Hypertension 2002;39:99-104.
17. Hartmann FS, Amann-Zalan I, Hoersch S, Katus HA. Influence of creatinine on plasma concentrations and the prognostic value of N-terminal pro-BNP in severe chronic heart failure: data from a substudy of the Copernicus trial. J Am Coll Cardiol 2003;41: 143A.
18. Trapé J, Naval I, Pérez A, Comerma I, Escudero J, Sans A. N-terminal pro-brain natriuretic peptide in dialysis patients. Clin Chem Lab Med 2003;41:S450.
19. Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2000;46: 1529-34.
20. Mair J. Role of cardiac natriuretic peptide testing in heart failure. Clin Chem 2002;48:977-8.
21. Schulz H, Langvik TA, Lund Sagen E, Smith J, Ahmadi N, Hall C. Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma. Scan J Clin Lab Invest 2001;61:33-42.
22. Missbichler A, Hawa G, Woloszczuk W, Schmal N, Hartter E. Enzymimmunoassays für proBNP-Fragmente (8-29) und (32-57). J Lab Med 1999;23:241-4.
23. Hughes D, Talwar S, Squire IB, Davies JE, Ng LL. An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction. Clin Sci 1999;96:373-80.
24. Hallermayer K, Gallusser A, Seidel C, Schenk J, Karl J, Rippeghather G. Elecsys proBNP: a new routine immunoassay to support diagnosis of chronic heart failure (CHF). Clin Chem Lab Med 2001;39:S194.
25. Seidler T, Pemberton C, Yandle T, Espiner E, Nicholls G, Richards M. The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiled-coil motifs. Biochim Biophys Res Commun 1999;255:495-501.
26. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem 2003;49:976-9.
27. Luthe H, Baum H, Collinson P, et al. Elecsys proBNP: evaluation of the technical performance in a multicenter study. Clin Chem Lab Med 2002;40:S313.
28. Goetze JP, Kastrup J, Pedersen F, Rehfeld JF. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem 2002;48:1035-42.
29. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls G, Richards M. Plasma amino-terminal B-type natriuretic peptide measured by Elecsys 2010 assay in a trial of hormone-guided treatment for heart failure. Clin Chem 2003;49: 1212-5.
30. Raymond I, Groenning BA, Hildebrandt PR, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89:745-51.
31. Raymond I, Groenning BA, Pedersen F, et al. N-terminal pro brain natriuretic peptide plasma levels is dependent of age anf gender: a survey of a large urban population aged older than fifty years. J Am Coll Cardiol 2001;37(suppl):147A.
32. Giannessi D, Andreassi MG, Del Ry S, Clerico A, Colombo MG, Dini N. Possibility of age regulation of the natriuretic peptide C-receptor in human platelets. J Endocrinol Invest 2001;24: 8-16.
33. Maffei S, Del Ry S, Prontera C, Clerico A. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Clin Sci 2001;101: 447-53.
34. Rauh M, Koch A. Plasma N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children. Clin Chem 2003;49:1563-4.
35. Pagani F, Stefini F, Panteghini M. Biological variation in serum concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP). Clin Chem 2003;49:A34.
36. Harris EK. Effects of intra- and inter-individual variation on the appropriate use of normal range. Clin Chem 1974;20:1535-42.
37. Bettencourt P, Ferreira S, Azevedo A, Ferreira A. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. Am J Med 2002; 113:215-9.
38. Wu AHB, Smith A, Wieczorek S, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003;92:628-31.
39. Hermann KM, Hanusch-Enserer U, Graenitz-Trisko CH, Pollak J, Köller U. Normalization of elevated plasma levels of amino-terminal pro-brain natriuretic peptide (NT-PROBNP) after surgically induced massive weight-loss in morbid obese female. Clin Chem Lab Med 2003;41:S426.
40. Herrmann M, Scharhag J, Miclea M, Urhausen A, Hermann W, Kindermann W. Post-race kinetics of cardiac troponin T and I and N-terminal pro-brain natriuretic peptide in marathon runners, Clin Chem 2003;49:831-4.
41. Wijbenga JAM, Balk AHMM, Boomsma F, Man in't Veld AJ, Hall C. Cardiac peptides differ in their response to exercise. Eur Heart J 1999;20:1424-8.
42. Maisel A. B-type natriuretic peptide levels: a potential novel "white blood count" for congestive heart failure: J Card Fail 2001;7:183-93.
43. Gøtze JP, Kastrup J. Plasma pro-brain natriuretic peptides are strong biochemical markers in clinical cardiology. Scan J Clin Lab Invest 2001;61 (suppl 234):47-51.